Intravenous immunoglobulin (IVIg)

Intravenous immunoglobulin (IVIg) is a solution of human plasma proteins and in particular IgG antibodies with a broad spectrum of antibody activity. IVIg is prepared from large pools of human plasma collected from several thousand blood donors and contains the typical IgG antibodies found in the normal population. IVIg is used for patients who need replacement of antibodies and also for autoimmune disorders.

IVIg can be obtained under National Blood Supply or Direct Order arrangements. Refer to the National Blood Authority website about the supply of IVIg in Australia.

Prescription of IVIg often requires specialist consultation. Always read and refer to the product information sheet of every product prior to administration.

Introduction of Intragam® 10

From 1 March 2017 a 10% formulation of IVIg is being introduced. Intragam® 10 is an Australian manufactured IVIg product and will eventually replace Intragam® P, the current 6% formulation.

Intragam® 10 provides a lower infusion volume per dose compared to the equivalent dose of Intragam® P.
 

Criteria for the clinical use of intravenous immunoglobulin

Intravenous immunoglobulin (IVIg) is issued in accordance with the Criteria for the Clinical Use of Intravenous Immunoglobulin in Australia.

The criteria describe the conditions and circumstances for which IVIg is funded under the national blood supply arrangements.
 

Access to intravenous immunoglobulin 

In all states/territories except NSW government funded IVIg is accessed online by registered users of BloodSTAR.   

BloodSTAR is the National Blood Authority’s online system that facilitates authorisation, dispensing and reviews of immunoglobulin products such as IVIg. To register for BloodSTAR you will need to create an account with the National Blood Authority’s BLOODportal.

 

IVIg authorisation request forms (NSW only)

In NSW to access government funded IVIg please use the IVIg “Authorisation Request Forms” available on the National Blood Authority website. 

The forms have two pages that will need to be completed by the Prescriber and submitted to the Australian Red Cross Blood Service for assessment in accordance with the Criteria for the Clinical Use of IVIg.

►Download weekly order form (NSW only)

 

Intragam® P is an Australian manufactured IVIg product and is accessed under the National Blood Supply (NBS) arrangements.

Intragam® P is supplied by CSL Behring an available as a 6% solution in vial sizes 3g/50 mL and 12g/200 mL.

Refer to the Criteria for the Clinical Use of IVIg for specific indications and product information sheet for further information.

Information on supply and pricing is outlined in the National Blood Authority website.

Intragam® P product information

This link takes you to CSL Behring's web information about Intragam® P where you can download the product information (PI) sheet for this product. The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, and dosage & administration of Intragam® P.

► Read the infusion rate for Intragam® P

Intragam® 10 is an Australian manufactured IVIg product and is being introduced to replace Intragam® P. Intragam® 10 is accessed under the National Blood Supply (NBS) arrangements.

Intragam® 10 is supplied by CSL Behring and available as a 10% solution in sizes: 2.5g/25 mL, 10g/ 100 mL and 20g/200 mL.

Refer to the Criteria for the Clinical Use of IVIg for specific indications and product information sheet for further information.

Information on supply and pricing is outlined in the National Blood Authority website.

Intragam® 10 product information 

 

This link takes you to CSL Behring's web information about Intragam® 10  where you can download the product information (PI) sheet for this product. The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, and dosage & administration of Intragam® 10. 

Privegen® is an imported IVIg product.

Privigen® is supplied by CSL Behring and available as a 10% solution in vial sizes 5g/50 mL, 10g/100 mL, 20g/200 mL and 40g/400 mL.

Refer to the Criteria for the Clinical Use of IVIg for specific indications and product information sheet for further information.

Information on supply and pricing is outlined in the National Blood Authority website.

Privigen® product information and educational materials

This link takes you to CSL Behring's web information about Privigen®  where you can download the product information (PI) sheet for this product. The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, and dosage & administration of Privigen®. You can also download an order form to request copies of educational materials.

Flebogamma® is an imported IVIg product. Flebogamma® is supplied by Grifols and available in both 5% and 10% formulations.

Refer to the Criteria for the Clinical Use of IVIg for specific indications and product information sheet for further information.

Information on supply and pricing is outlined in the National Blood Authority website.

 

Flebogamma® 5% DIF

Flebogamma® 5% DIF is available in vial sizes 0.5g/10 mL, 2.5g/50 mL, 5g/100 mL, 10g/200 mL and 20g/400 mL.

Flebogamma® 5% product information

This link takes you to Grifol's web information about Flebogamma® 5% DIF where you can download the product information (PI) sheet for this product. The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, and dosage and administration of Flebogamma® 5% DIF.

 

Flebogamma® 10% DIF

Flebogamma® 10% DIF is available in vial sizes 5g/50 mL, 10g/100 mL and 20g/200 mL.

Flebogamma® 10% product information

This link takes you to Grifol's web information about Flebogamma® 10% DIF where you can download the product information (PI) sheet for this product. The PI details the pharmacology, indications, contraindications, precautions, adverse effects, use in pregnancy & lactation, and dosage and administration of Flebogamma® 10% DIF.

Further information

The Australian Immunisation Handbook recommends that immunoglobulin containing blood products, apart from RhD Immunoglobulin (“Anti-D”), should not be administered for 3 weeks following vaccination with live attenuated vaccines. MMR containing vaccines should not be given for 3-11 months following the receipt of immunoglobulin containing blood products. Further information regarding all vaccines should be obtained from the Australian Immunisation Handbook 10th edition.

► Supply of plasma derived and recombinant blood products factsheet

►Download the comparison of Intragam® P, Intragam® 10, Privigen® and Flebogamma®